Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bicara Therapeutics Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing bifunctional therapies for solid tumors. Forms 8-K record financial results, business highlights, ficerafusp alfa clinical updates, material definitive agreements and other events, including common stock and pre-funded warrant financing.
The company’s proxy materials cover annual meeting proposals, board-class elections, auditor ratification and governance matters for an emerging growth company. The filings also describe capital-structure actions and formal exhibits tied to press releases, underwriting agreements and shareholder voting matters.
Bicara Therapeutics Inc. is a clinical-stage oncology company focused on bifunctional antibody therapy ficerafusp alfa for solid tumors, particularly head and neck cancers. It reported a net loss of $55.4 million for the quarter and $111.6 million for the first half of 2026, reflecting heavier investment in R&D and corporate build-out.
Quarterly operating expenses rose to $60.0 million, driven by $45.8 million in research and development and $14.2 million in general and administrative costs, including higher clinical, manufacturing and stock-based compensation expenses. Cash used in operating activities was $81.7 million in the first half.
Bicara strengthened its balance sheet via a February 2026 equity and pre-funded warrant offering, bringing cash, cash equivalents and marketable securities to $497.3 million as of June 30, 2026 and total equity to $468.8 million. Management believes this capital will fund operations into the first half of 2029 while advancing the Phase 2/3 FORTIFI-HN01 pivotal trial and additional studies of ficerafusp alfa.
Bicara Therapeutics Inc. reported second quarter 2026 results and major leadership changes while advancing its lead oncology program ficerafusp alfa. Ryan Cohlhepp will become President and CEO on January 1, 2027, with current CEO Claire Mazumdar transitioning to Vice Chair of the Board and Strategic Advisor. Additional senior hires include a new CFO, Chief Business Officer and Chief Legal Officer, reflecting preparations for potential commercialization.
The company is enrolling the pivotal Phase 3 FORTIFI-HN01 trial in first-line recurrent or metastatic HPV-negative head and neck cancer and expects substantial enrollment by year-end, enabling interim topline data in mid-2027. A new FORTIFI-FLEX alternate dosing study has begun. Three-year follow-up from a Phase 1/1b cohort showed an estimated overall survival rate of 31%, approximately doubling survival seen in retrospective standard-of-care pembrolizumab data.
Financially, Bicara ended June 30, 2026 with $497.3 million in cash, cash equivalents and marketable securities and expects this to fund operations into the first half of 2029. Second quarter 2026 research and development expenses were $45.8 million and general and administrative expenses were $14.2 million, driving a net loss of $55.4 million, all higher than the prior-year period.
BCAX insider Ivan Hyep filed to sell common shares through UBS Financial Services. The notice covers 12,500 common shares with an aggregate market value of $347,875.00, expected to be sold on 08/10/2026, in connection with the exercise of stock options for cash.
The filing also lists prior sales over the past three months: 9,200 common shares for $187,883.32 on 05/21/2026 and 28,000 common shares for $807,671.05 on 07/08/2026.
BCAX affiliate Ryan Cohlhepp filed to sell up to 18,750 common shares through broker UBS Financial Services, Inc. The planned sale is tied to an Exercise of Stock Option and is scheduled for 08/10/2026 on NASDAQ, with an aggregate market value of $521,812.50.
Over the prior three months, Cohlhepp reported BCAX common stock sales of 12,500 shares for $253,648.75 on 05/15/2026, 28,214 shares for $817,584.36 on 07/08/2026, and 536 shares for $15,544.00 on 07/09/2026.
BCAX insider Claire Mazumdar plans to sell 10,000 shares of common stock through UBS Financial Services on 08/10/2026, following an exercise of stock options for cash. The planned sale has a proposed aggregate value of $278,300.00.
In the preceding three months, Mazumdar sold 15,000 common shares for $300,577.50 on 05/18/2026 and 10,000 shares for $284,994.00 on 07/10/2026.
Bicara Therapeutics director Jeremy Bender reported an equity compensation award in the form of a Stock Option (Right to Buy) covering 38,950 shares of common stock. The option has an exercise price of $26.88 per share and expires on July 28, 2036. One-third of the shares underlying the option vest and become exercisable on July 28, 2027, with the remaining shares vesting in 24 equal monthly installments thereafter, subject to his continued service on each vesting date.
Bicara Therapeutics Inc. director Christy J. Oliger received a grant of stock options for 38,950 shares of common stock on July 28, 2026. The options have an exercise price of $26.88 per share, expire on July 28, 2036, and vest one-third on July 28, 2027, with the remaining two-thirds vesting in 24 equal monthly installments, subject to her continued service.
Bicara Therapeutics Inc. reports that Jeremy Bender is a director of the company and has submitted an initial statement of beneficial ownership. The report lists no transactions or specific equity holdings for him, and references an accompanying Exhibit 24 - Power of Attorney.
Bicara Therapeutics Inc. submitted an initial beneficial ownership report for director Christy J. Oliger. The report lists no equity or derivative security transactions and does not list any current holdings or derivative positions. A remark references Exhibit 24, identified as a Power of Attorney.
Bicara Therapeutics Inc. reported that Kiran Mazumdar‑Shaw will resign from its Board and Nominating and Corporate Governance Committee effective July 28, 2026; her decision was stated not to result from any disagreement with the company. The Board appointed Jeremy Bender as a Class I director through the 2028 annual meeting and Christy Oliger as a Class II director through the 2029 meeting, effective the same date, and increased the authorized Board size from nine to ten directors.
Both new directors are deemed independent under Nasdaq rules and, as non‑employee directors, will receive compensation that includes an initial stock option award of 38,950 shares of common stock and cash fees under Bicara’s director compensation policy. Bender joins the Audit Committee, while Oliger and Carolyn Ng join the Nominating and Corporate Governance Committee. The Board also created a Launch Readiness Committee, including Bender, Oliger and chair Kate Haviland, to provide strategic and operational guidance on Bicara’s commercialization strategy and launch readiness for its lead program, ficerafusp alfa.